Search results for "Breakthrough-episodic pain"

showing 3 items of 3 documents

The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids

2017

Objective: The aim of this study was to prospectively assess the efficacy and safety of low doses of sublingual fentanyl (SLF) for the treatment of breakthrough pain (BTP) in cancer patients in patients who were receiving low opioid doses for background analgesia. Methods: A sample of cancer patients presenting BTP episodes and receiving stable low doses of opioids for background pain (less than 60 mg of oral morphine equivalents) was selected to assess the efficacy and safety of low doses of SLF (67 μg). For each patient, data from four consecutive episodes were collected. For each episode, changes in pain intensity and adverse effects when pain got severe (T0), and 5, 10, and 15 min a…

MaleBreakthrough-episodic pain; Cancer pain; Opioids; Sublingual tablet; OncologyBreakthrough PainPain medicineAdministration SublingualOpioidFentanyl03 medical and health sciences0302 clinical medicineBreakthrough-episodic painmedicineHumansIn patientProspective StudiesCancer painProspective cohort studySublingual tabletAgedbusiness.industryLow doseBreakthrough PainOpioidsAnalgesics OpioidFentanylProspective StudieOpioidOncology030220 oncology & carcinogenesisAnesthesiaFemaleCancer painbusiness030217 neurology & neurosurgerymedicine.drugHuman
researchProduct

The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

2013

Abstract The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from fou…

MalePain medicineSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataHome careFentanylDose-Response RelationshipBuccalBreakthrough-episodic painNeoplasmsmedicine80 and overHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalgesicsDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalBuccal administrationMiddle AgedFentanyl buccal tabletHome Care ServicesAnalgesics OpioidOpioidsFentanylRegimenTreatment OutcomeBasal (medicine)OpioidOncologyCancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home careAnesthesiaAdministrationFemaleBreakthrough-episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids; Administration Buccal; Aged; Aged 80 and over; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Home Care Services; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Treatment Outcome; OncologyDrugCancer painbusinessmedicine.drugTablets
researchProduct

Intravenous morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study.

2007

The aim of this prospective cohort study was to confirm the safety of intravenous morphine (IV-M) used in doses proportional to the basal opioid regimen for the management of breakthrough pain and to record the nurse compliance on regularly recording data regarding breakthrough pain treated by IV-M. Over a one-year period, 99 patients received IV-M for breakthrough pain during 116 admissions. The IV-M dose was 1/5 of the oral daily dose, converted using an equianalgesic ratio of 1/3 (IV/oral). For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to reassess the patient 15minutes after IV-M injection (…

MalePalliative carePainCancer pain breakthrough-episodic pain intravenous morphineMedicineHumansProspective StudiesAdverse effectProspective cohort studyGeneral NursingAgedMorphinebusiness.industryPalliative CareMiddle AgedEquianalgesicClinical trialAnalgesics OpioidRegimenAnesthesiology and Pain MedicineOpioidAnesthesiaInjections IntravenousFemaleNeurology (clinical)businessCancer painmedicine.drugJournal of pain and symptom management
researchProduct